AVE avecho biotechnology limited

Ann: Phosphagenics Entitlement Offer Raises Over AUD3M, page-24

  1. 2,106 Posts.
    lightbulb Created with Sketch. 461
    On reflection I think you are right SO. As RM said at the investor presentations recently, we just need to send the message that we are here for the duration of the arbitration. Given that the arbitration is probably occurring as we speak and that the decision is expected within 3-6 months, this amount of money achieves that.
    Mylan can't appeal the outcome of the arbitration (unless on a point of law), they have little room to delay this process now. It is now down to two decisions, one of the arbitrator and one of Mylan. The former being does the arbitrator accepts our case, the latter being does Mylan think that the arbitrator will and are they prepared to risk a $300 million dollar outcome or try to risk management and offer a reduced figure hoping POH accepts.
    Running Parallel to this is our work with Terumo, Credit Pharma and the animal health sector. I would assume that this week is the end of a lot of work by the management of POH. There is little more they can do to influence an outcome.
    That time and energy has now been released from the confines of arbitration. I would assume that RM has probably had to manage his time around these dates and possibly over the next few weeks he may be rather busy refocusing on those deals we already have.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.5¢
Change
0.000(0.00%)
Mkt cap ! $15.86M
Open High Low Value Volume
0.5¢ 0.5¢ 0.5¢ $6.364K 1.292M

Buyers (Bids)

No. Vol. Price($)
55 45046678 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 8245807 6
View Market Depth
Last trade - 14.24pm 08/08/2025 (20 minute delay) ?
AVE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.